U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937229) titled 'A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)' on April 15.
Brief Summary: The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
Study Start Date: Nov. 24, 2025
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Agitation
Intervention:
DRUG: KarXT
Speci...